The p2x7 receptor channel: Recent developments and the use of p2x7 antagonists in models of disease

Pharmacological Reviews

Volumn 66, Issue 3, 2014, Pages 638-675

  Bartlett, Rachael ^a,b   Stokes, Leanne ^c   Sluyter, Ronald ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b ILLAWARRA HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; PROSTAGLANDIN; PROTEINASE; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2X7 RECEPTOR ANTAGONIST; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CHANNEL GATING; CYTOKINE RELEASE; DISEASE MODEL; EFFUSION; ENZYME ACTIVATION; EXPERIMENTAL DOG; EXPERIMENTAL GUINEA PIG; HUMAN; KNOCKOUT MOUSE; MAMMAL; MUSCULOSKELETAL DISEASE; NERVOUS SYSTEM INFLAMMATION; NERVOUS SYSTEM INJURY; NEUROLOGIC DISEASE; NONHUMAN; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RHESUS MONKEY; RODENT MODEL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, GENETIC; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION;

EID: 84908232996     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.113.008003     Document Type: Article

References (365)

1. Abberley L, Bebius A, Beswick PJ, Billinton A, Collis KL, Dean DK, Fonfria E, Gleave RJ, Medhurst SJ, and Michel AD, et al. (2010) Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptor. Bioorg Med Chem Lett 20:6370–6374.
2. Abd Elmageed ZY, Naura AS, Errami Y, and Zerfaoui M (2012) The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell Signal 24:1–8.
3. Acuña-Castillo C, Coddou C, Bull P, Brito J, and Huidobro-Toro JP (2007) Differential role of extracellular histidines in copper, zinc, magnesium and proton modulation of the P2X7 purinergic receptor. J Neurochem 101:17–26.
4. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR, Pinton P, Rizzuto R, and Di Virgilio F (2005) Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 16:3260–3272.
5. Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandonà D, Markwardt F, and Schmalzing G, et al. (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24: 3393–3404.
6. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, and Di Virgilio F (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72:2957–2969.
7. Adriouch S, Dox C, Welge V, Seman M, Koch-Nolte F, and Haag F (2002) Cutting edge: a natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X7 receptor. J Immunol 169:4108–4112.
8. Adriouch S, Ohlrogge W, Haag F, Koch-Nolte F, and Seman M (2001) Rapid induction of naive T cell apoptosis by ecto-nicotinamide adenine dinucleotide: requirement for mono(ADP-ribosyl)transferase 2 and a downstream effector. J Immunol 167: 196–203.
9. Aktories K (2011) Bacterial protein toxins that modify host regulatory GTPases. Nat Rev Microbiol 9:487–498.
10. Al-Shukaili A, Al-Kaabi J, Hassan B, Al-Araimi T, Al-Tobi M, Al-Kindi M, Al-Maniri A, Al-Gheilani A, and Al-Ansari A (2011) P2X7 receptor gene polymorphism analysis in rheumatoid arthritis. Int J Immunogenet 38:389–396.
11. Alberto AVP, Faria RX, Couto CGC, Ferreira LGB, Souza CAM, Teixeira PCN, Fróes MM, and Alves LA (2013) Is pannexin the pore associated with the P2X7 receptor? Naunyn Schmiedebergs Arch Pharmacol 386:775–787.
12. Alcaraz L, Baxter A, Bent J, Bowers K, Braddock M, Cladingboel D, Donald D, Fagura M, Furber M, and Laurent C, et al. (2003) Novel P2X7 receptor antagonists. Bioorg Med Chem Lett 13:4043–4046.
13. Andó RD, Méhész B, Gyires K, Illes P, and Sperlágh B (2010) A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J Pharmacol 159:1106–1117.
14. 2 control lysosome-mediated IL-1b secretion: Implications for inflammatory processes. Proc Natl Acad Sci USA 101:9745–9750.
15. Apolloni S, Parisi C, Pesaresi MG, Rossi S, Carrì MT, Cozzolino M, Volonté C, and D’Ambrosi N (2013) The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis. J Immunol 190:5187–5195.
16. Arbeloa J, Pérez-Samartín A, Gottlieb M, and Matute C (2012) P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol Dis 45:954–961.
17. Ardissone V, Radaelli E, Zaratin P, Ardizzone M, Ladel C, Gattorno M, Martini A, Grassi F, and Traggiai E (2011) Pharmacologic P2X purinergic receptor antagonism in the treatment of collagen-induced arthritis. Arthritis Rheum 63:3323–3332.
18. 2 underlies glutamate-dependent inhibition of striatal dopamine release. Proc Natl Acad Sci USA 100:11729–11734.
19. Baas T (2012) Paradoxical P2X7. SciBX 5:5–7.
20. Banke TG, Chaplan SR, and Wickenden AD (2010) Dynamic changes in the TRPA1 selectivity filter lead to progressive but reversible pore dilation. Am J Physiol Cell Physiol 298:C1457-C1468.
21. 2 and IL-1/3 release. FASEB J 26:2951-2962.
22. Barden N, Harvey M, Gagné B, Shink E, Tremblay M, Raymond C, Labbé M, Vil-leneuve A, Rochette D, and Bordeleau L, et al. (2006) Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuro-psychiatr Genet 141B:374-382.
23. Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E, Rubini M, and Di Virgilio F (1996) An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 87:682-690.
24. Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, and Di Virgilio F (1999) Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem 274:33206-33208.
25. Bartlett R, Yerbury JJ, and Sluyter R (2013) P2X7 receptor activation induces reactive oxygen species formation and cell death in murine EOC13 microglia. Mediators Inflamm 2013:271813.
26. Basso AM, Bratcher NA, Harris RR, Jarvis MF, Decker MW, and Rueter LE (2009) Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res 198:83-90.
27. Beigi RD, Kertesy SB, Aquilina G, and Dubyak GR (2003) Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br J Pharmacol 140:507-519.
28. Bhaskaracharya A, Dao-Ung P, Jalilian I, Spildrejorde M, Skarratt KK, Fuller SJ, Sluyter R, and Stokes L (2014) Probenecid blocks human P2X7 receptor-induced dye uptake via a pannexin-1 independent mechanism. PLoS ONE 9:e93058.
29. Bhattacharya A, Neff RA, and Wickenden AD (2011) The physiology, pharmacology and future of P2X7 as an analgesic drug target: hype or promise? Curr Pharm Biotechnol 12:1698-1706.
30. Bhattacharya A, Wang Q, Ao H, Shoblock JR, Lord B, Aluisio L, Fraser I, Nepomuceno D, Neff RA, and Welty N, et al. (2013) Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol 170: 624-640.
31. Bianchi BR, Lynch KJ, Touma E, Niforatos W, Burgard EC, Alexander KM, Park HS, Yu H, Metzger R, and Kowaluk E, et al. (1999) Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 376: 127-138.
32. Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D, Pizzirani C, Matteoli M, Di Virgilio F, Abbracchio MP, and Verderio C (2006) A role for P2X7 in microglial proliferation. J Neurochem 99:745-758.
33. Boucher AA, Arnold JC, Hunt GE, Spiro A, Spencer J, Brown C, McGregor IS, Bennett MR, and Kassiou M (2011) Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 189:170-177.
34. Bradley HJ, Baldwin JM, Goli GR, Johnson B, Zou J, Sivaprasadarao A, Baldwin SA, and Jiang L-H (2011a) Residues 155 and 348 contribute to the determination of P2X7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J Biol Chem 286:8176-8187.
35. Bradley HJ, Browne LE, Yang W, and Jiang LH (2011b) Pharmacological properties of the rhesus macaque monkey P2X7 receptor. Br J Pharmacol 164 (2b):743-754.
36. Brandao-Burch A, Key ML, Patel JJ, Arnett TR, and Orriss IR (2012) The P2X7 receptor is an important regulator of extracellular ATP levels. Front Endocrinol (Lausanne) 3:41.
37. Broom DC, Matson DJ, Bradshaw E, Buck ME, Meade R, Coombs S, Matchett M, Ford KK, Yu W, and Yuan J, et al. (2008) Characterization of N-(adamantan-1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation. J Pharmacol Exp Ther 327: 620-633.
38. Browne LE, Compan V, Bragg L, and North RA (2013) P2X7 receptor channels allow direct permeation of nanometer-sized dyes. J Neurosci 33:3557-3566.
39. Buchanan MS, Carroll AR, Addepalli R, Avery VM, Hooper JN, and Quinn RJ (2007a) Natural products, stylissadines A and B, specific antagonists of the P2X7 receptor, an important inflammatory target. J Org Chem 72:2309-2317.
40. Buchanan MS, Carroll AR, Addepalli R, Avery VM, Hooper JN, and Quinn RJ (2007b) Niphatoxin C, a cytotoxic tripyridine alkaloid from Callyspongia sp. J Nat Prod 70:2040-2041.
41. Budai MM, Varga A, Milesz S, Tozsér J, and Benko S (2013) Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflam-masome in human macrophages. Mol Immunol 56:471-479.
42. Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, Gretener D, Grahames C, Kaur R, and Kosco-Vilbois MH, et al. (1998) Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92:3521-3528.
43. Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509-581.
44. Burnstock G (2006) Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58:58-86.
45. Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64:1471-1483.
46. Burnstock G and Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31-304.
47. Cabrini G, Falzoni S, Forchap SL, Pellegatti P, Balboni A, Agostini P, Cuneo A, Castoldi G, Baricordi OR, and Di Virgilio F (2005) A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol 175:82-89.
48. Cario-Toumaniantz C, Loirand G, Ferrier L, and Pacaud P (1998) Non-genomic inhibition of human P2X7 purinoceptor by 17b-oestradiol. J Physiol 508:659-666.
49. Cascabulho CM, Bani Corrêa C, Cotta-de-Almeida V, and Henriques-Pons A (2012) Defective T-lymphocyte migration to muscles in dystrophin-deficient mice. Am J Pathol 181:593-604.
50. Cervetto C, Alloisio S, Frattaroli D, Mazzotta MC, Milanese M, Gavazzo P, Passalacqua M, Nobile M, Maura G, and Marcoli M (2013a) The P2X7 receptor as a route for non-exocytotic glutamate release: dependence on the carboxyl tail. J Neurochem 124: 821–831.
51. Cervetto C, Frattaroli D, Maura G, and Marcoli M (2013b) Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism. Toxicology 311:69–77.
52. Chatterjee S, Rana R, Corbett J, Kadiiska MB, Goldstein J, and Mason RP (2012) P2X7 receptor-NADPH oxidase axis mediates protein radical formation and Kupffer cell activation in carbon tetrachloride-mediated steatohepatitis in obese mice. Free Radic Biol Med 52:1666–1679.
53. Chaumont S and Khakh BS (2008) Patch-clamp coordinated spectroscopy shows P2X2 receptor permeability dynamics require cytosolic domain rearrangements but not Panx-1 channels. Proc Natl Acad Sci USA 105:12063–12068.
54. Cheewatrakoolpong B, Gilchrest H, Anthes JC, and Greenfeder S (2005) Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun 332:17–27.
55. -/- mice: evidence for loss of apoptotic activity in lymphocytes. J Immunol 176:3115–3126.
56. Chen ML, Cao H, Chu YX, Cheng LZ, Liang LL, Zhang YQ, and Zhao ZQ (2012) Role of P2X7 receptor-mediated IL-18/IL-18R signaling in morphine tolerance: multiple glial-neuronal dialogues in the rat spinal cord. J Pain 13:945–958.
57. Chen S, Ma Q, Krafft PR, Chen Y, Tang J, Zhang J, and Zhang JH (2013a) P2X7 receptor antagonism inhibits p38 mitogen-activated protein kinase activation and ameliorates neuronal apoptosis after subarachnoid hemorrhage in rats. Crit Care Med 41:e466–e474.
58. Chen S, Ma Q, Krafft PR, Hu Q, Rolland WII, Sherchan P, Zhang J, Tang J, and Zhang JH (2013b) P2X7R/cryopyrin inflammasome axis inhibition reduces neuroinflammation after SAH. Neurobiol Dis 58:296–307.
59. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, and Peck WL, et al. (2005) Disruption of the P2X7 puri-noceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114: 386–396.
60. Chessell IP, Simon J, Hibell AD, Michel AD, Barnard EA, and Humphrey PPA (1998) Cloning and functional characterisation of the mouse P2X7 receptor. FEBS Lett 439:26–30.
61. Chiao CW, da Silva-Santos JE, Giachini FR, Tostes RC, Su MJ, and Webb RC (2013) P2X7 receptor activation contributes to an initial upstream mechanism of lipopolysaccharide-induced vascular dysfunction. Clin Sci (Lond) 125:131–141.
62. Choi HB, Ryu JK, Kim SU, and McLarnon JG (2007) Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain. J Neurosci 27:4957–4968.
63. Chow SC, Kass GEN, and Orrenius S (1997) Purines and their roles in apoptosis. Neuropharmacology 36:1149–1156.
64. Chu K, Yin B, Wang J, Peng G, Liang H, Xu Z, Du Y, Fang M, Xia Q, and Luo B (2012) Inhibition of P2X7 receptor ameliorates transient global cerebral ischemia/ reperfusion injury via modulating inflammatory responses in the rat hippocampus. J Neuroinflammation 9:69.
65. Chu YX, Zhang Y, Zhang YQ, and Zhao ZQ (2010) Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Brain Behav Immun 24:1176–1189.
66. Chung M-K, Güler AD, and Caterina MJ (2008) TRPV1 shows dynamic ionic selectivity during agonist stimulation. Nat Neurosci 11:555–564.
67. Clark AK, Staniland AA, Marchand F, Kaan TKY, McMahon SB, and Malcangio M (2010) P2X7-dependent release of interleukin-1b and nociception in the spinal cord following lipopolysaccharide. J Neurosci 30:573–582.
68. Cockcroft S and Gomperts BD (1979) Activation and inhibition of calcium-dependent histamine secretion by ATP ions applied to rat mast cells. J Physiol 296:229–243.
69. Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, and Stojilkovic SS (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63: 641–683.
70. Compan V, Baroja-Mazo A, López-Castejón G, Gomez AI, Martínez CM, Angosto D, Montero MT, Herranz AS, Bazán E, and Reimers D, et al. (2012a) Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 37:487–500.
71. Compan V, Ulmann L, Stelmashenko O, Chemin J, Chaumont S, and Rassendren F (2012b) P2X2 and P2X5 subunits define a new heteromeric receptor with P2X7-like properties. J Neurosci 32:4284–4296.
72. Csölle C, Baranyi M, Zsilla G, Kittel A, Gölöncsér F, Illes P, Papp E, Vizi ES, and Sperlágh B (2013) Neurochemical changes in the mouse hippocampus underlying the antidepressant effect of genetic deletion of P2X7 receptors. PLoS ONE 8:e66547.
73. Csölle C and Sperlágh B (2010) Peripheral origin of IL-1b production in the rodent hippocampus under in vivo systemic bacterial lipopolysaccharide (LPS) challenge and its regulation by P2X(7) receptors. J Neuroimmunol 219:38–46.
74. da Silva GL, Sperotto NDM, Borges TJ, Bonorino C, Takyia CM, Coutinho-Silva R, Campos MM, Zanin RF, and Morrone FB (2013) P2X7 receptor is required for neutrophil accumulation in a mouse model of irritant contact dermatitis. Exp Dermatol 22:184–188.
75. Delarasse C, Auger R, Gonnord P, Fontaine B, and Kanellopoulos JM (2011) The purinergic receptor P2X7 triggers a-secretase-dependent processing of the amyloid precursor protein. J Biol Chem 286:2596–2606.
76. Dell’Antonio G, Quattrini A, Cin ED, Fulgenzi A, and Ferrero ME (2002a) Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum 46:3378–3385.
77. Dell’Antonio G, Quattrini A, Dal Cin E, Fulgenzi A, and Ferrero ME (2002b) Anti-nociceptive effect of a new P(2Z)/P2X7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett 327:87–90.
78. Di Virgilio F (2013) The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol Rev 65:872–905.
79. Diaz-Hernandez JI, Gomez-Villafuertes R, León-Otegui M, Hontecillas-Prieto L, Del Puerto A, Trejo JL, Lucas JJ, Garrido JJ, Gualix J, and Miras-Portugal MT, et al. (2012) In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3b and secretases. Neurobiol Aging 33:1816–1828.
80. Díaz-Hernández M, Díez-Zaera M, Sánchez-Nogueiro J, Gómez-Villafuertes R, Canals JM, Alberch J, Miras-Portugal MT, and Lucas JJ (2009) Altered P2X7-receptor level and function in mouse models of Huntington’s disease and therapeutic efficacy of antagonist administration. FASEB J 23:1893–1906.
81. Donnelly-Roberts DL and Jarvis MF (2007) Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151:571–579.
82. Donnelly-Roberts DL, Namovic MT, Faltynek CR, and Jarvis MF (2004) Mitogen-activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-induced pore formation in human THP-1 cells. J Pharmacol Exp Ther 308:1053–1061.
83. Donnelly-Roberts DL, Namovic MT, Han P, and Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157:1203–1214.
84. Duan S, Anderson CM, Keung EC, Chen Y, Chen Y, and Swanson RA (2003) P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 23: 1320–1328.
85. Dunn PM and Blakeley AGH (1988) Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol 93:243–245.
86. Duplantier AJ, Dombroski MA, Subramanyam C, Beaulieu AM, Chang SP, Gabel CA, Jordan C, Kalgutkar AS, Kraus KG, and Labasi JM, et al. (2011) Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. Bioorg Med Chem Lett 21:3708–3711.
87. z purinergic receptors in BAC1.2F5 macrophages. J Biol Chem 267:23664–23673.
88. 7 receptors in murine peritoneal macrophages. Prostaglandins Other Lipid Mediat 99:116–123.
89. Elssner A, Duncan M, Gavrilin M, and Wewers MD (2004) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1b processing and release. J Immunol 172:4987–4994.
90. Eltom S, Stevenson CS, Rastrick J, Dale N, Raemdonck K, Wong S, Catley MC, Belvisi MG, and Birrell MA (2011) P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS ONE 6:e24097.
91. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, and Protter AA (1993) CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268: 11811–11816.
92. Engel T, Gomez-Villafuertes R, Tanaka K, Mesuret G, Sanz-Rodriguez A, Garcia-Huerta P, Miras-Portugal MT, Henshall DC, and Diaz-Hernandez M (2012) Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J 26:1616–1628.
93. Evans RJ, Lewis C, Buell G, Valera S, North RA, and Surprenant A (1995) Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors). Mol Pharmacol 48:178–183.
94. 7 receptor. J Neurosci Res 89:199–211.
95. Faria RX, Defarias FP, and Alves LA (2005) Are second messengers crucial for opening the pore associated with P2X7 receptor? Am J Physiol Cell Physiol 288: C260–C271.
96. 2+. Am J Physiol Cell Physiol 297:C28–C42.
97. Felix RA, Martin S, Pinion S, and Crawford DJ (2012) Development of a comprehensive set of P2 receptor pharmacological research compounds. Purinergic Signal 8 (Suppl 1):101–112.
98. Fellin T, Pozzan T, and Carmignoto G (2006) Purinergic receptors mediate two distinct glutamate release pathways in hippocampal astrocytes. J Biol Chem 281: 4274–4284.
99. Feng YH, Li X, Wang L, Zhou L, and Gorodeski GI (2006) A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem 281: 17228–17237.
100. Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Goldberg H, Marks GB, Wiley JS, and Britton WJ (2007) A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 175:360–366.
101. Ferrari D, Los M, Bauer MKA, Vandenabeele P, Wesselborg S, and Schulze-Osthoff K (1999) P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett 447:71–75.
102. Ferrari D, Pizzirani C, Adinolfi E, Forchap S, Sitta B, Turchet L, Falzoni S, Minelli M, Baricordi R, and Di Virgilio F (2004) The antibiotic polymyxin B modulates P2X7 receptor function. J Immunol 173:4652–4660.
103. Ferrari D, Wesselborg S, Bauer MKA, and Schulze-Osthoff K (1997) Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol 139:1635–1643.
104. Fonfria E, Clay WC, Levy DS, Goodwin JA, Roman S, Smith GD, Condreay JP, and Michel AD (2008) Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue. Br J Pharmacol 153:544–556.
105. Franke H, Krügel U, Grosche J, and Illes P (2003) Immunoreactivity for glial fibrillary acidic protein and P2 receptor expression on astrocytes in vivo. Drug Dev Res 59:175–189.
106. Franke H, Schepper C, Illes P, and Krügel U (2007) Involvement of P2X and P2Y receptors in microglial activation in vivo. Purinergic Signal 3:435–445.
107. Friedle SA, Curet MA, and Watters JJ (2010) Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. Recent Patents CNS Drug Discov 5:35–45.
108. Fulgenzi A, Dell’Antonio G, Foglieni C, Dal Cin E, Ticozzi P, Franzone JS, and Ferrero ME (2005) Inhibitionof chemokine expression in rat inflamed pawsby systemic use of the antihyperalgesic oxidized ATP. BMC Immunol 6:18.
109. Fulgenzi A, Ticozzi P, Gabel CA, Dell’Antonio G, Quattrini A, Franzone JS, and Ferrero ME (2008) Periodate oxidized ATP (oATP) reduces hyperalgesia in mice: involvement of P2X7 receptors and implications for therapy. Int J Immunopathol Pharmacol 21: 61–71.
110. Gadeock S, Tran JN, Georgiou JG, Jalilian I, Taylor RM, Wiley JS, and Sluyter R (2010) TGF-b1 prevents up-regulation of the P2X7 receptor by IFN-g and LPS in leukemic THP-1 monocytes. Biochim Biophys Acta 1798:2058–2066.
111. Garbers C, Jänner N, Chalaris A, Moss ML, Floss DM, Meyer D, Koch-Nolte F, Rose-John S, and Scheller J (2011) Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 286:14804–14811.
112. García-Huerta P, Díaz-Hernandez M, Delicado EG, Pimentel-Santillana M, Miras-Portugal MT, and Gómez-Villafuertes R (2012) The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system. J Biol Chem 287:44628–44644.
113. Gargett CE, Cornish JE, and Wiley JS (1997) ATP, a partial agonist for the P2Z receptor of human lymphocytes. Br J Pharmacol 122:911–917.
114. Gargett CE and Wiley JS (1997) The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol 120:1483–1490.
115. Gartland A, Buckley KA, Hipskind RA, Perry MJ, Tobias JH, Buell G, Chessell I, Bowler WB, and Gallagher JA (2003) Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice. Crit Rev Eukaryot Gene Expr 13: 243–253.
116. Gartland A, Skarratt KK, Hocking LJ, Parsons C, Stokes L, Jørgensen NR, Fraser WD, Reid DM, Gallagher JA, and Wiley JS (2012) Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur J Hum Genet 20: 559–564.
117. Gavala ML, Hill LM, Lenertz LY, Karta MR, and Bertics PJ (2010) Activation of the transcription factor FosB/activating protein-1 (AP-1) is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells. J Biol Chem 285:34288–34298.
118. Gavala ML, Pfeiffer ZA, and Bertics PJ (2008) The nucleotide receptor P2RX7 mediates ATP-induced CREB activation in human and murine monocytic cells. J Leukoc Biol 84:1159–1171.
119. Gever JR, Cockayne DA, Dillon MP, Burnstock G, and Ford AP (2006) Pharmacology of P2X channels. Pflugers Arch 452:513–537.
120. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, and Ullrich E, et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1b-dependent adaptive immunity against tumors. Nat Med 15:1170–1178.
121. Gidlöf O, Smith JG, Melander O, Lövkvist H, Hedblad B, Engström G, Nilsson P, Carlson J, Berglund G, and Olsson S, et al. (2012) A common missense variant in the ATP receptor P2X7 is associated with reduced risk of cardiovascular events. PLoS ONE 7:e37491.
122. Glas R, Sauter NS, Schulthess FT, Shu L, Oberholzer J, and Maedler K (2009) Puri-nergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival. Diabetologia 52:1579–1588.
123. Gonzales EB, Kawate T, and Gouaux E (2009) Pore architecture and ion sites in acid-sensing ion channels and P2X receptors. Nature 460:599–604.
124. Gourine AV, Poputnikov DM, Zhernosek N, Melenchuk EV, Gerstberger R, Spyer KM, and Gourine VN (2005) P2 receptor blockade attenuates fever and cyto-kine responses induced by lipopolysaccharide in rats. Br J Pharmacol 146: 139–145.
125. Gross O, Thomas CJ, Guarda G, and Tschopp J (2011) The inflammasome: an integrated view. Immunol Rev 243:136–151.
126. Gu B, Bendall LJ, and Wiley JS (1998) Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 92:946–951.
127. Gu BJ, Baird PN, Vessey KA, Skarratt KK, Fletcher EL, Fuller SJ, Richardson AJ, Guymer RH, and Wiley JS (2013) A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration. FASEB J 27:1479–1487.
128. Gu BJ, Duce JA, Valova VA, Wong B, Bush AI, Petrou S, and Wiley JS (2012) P2X7 receptor-mediated scavenger activity of mononuclear phagocytes toward non-opsonized particles and apoptotic cells is inhibited by serum glycoproteins but remains active in cerebrospinal fluid. J Biol Chem 287:17318–17330.
129. Gu BJ, Rathsam C, Stokes L, McGeachie AB, and Wiley JS (2009) Extracellular ATP dissociates nonmuscle myosin from P2X(7) complex: this dissociation regulates P2X(7) pore formation. Am J Physiol Cell Physiol 297:C430–C439.
130. Gu BJ, Saunders BM, Jursik C, and Wiley JS (2010) The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of nonopsonized particles and bacteria by a pathway attenuated by extracellular ATP. Blood 115:1621–1631.
131. Gu BJ, Saunders BM, Petrou S, and Wiley JS (2011) P2X(7) is a scavenger receptor for apoptotic cells in the absence of its ligand, extracellular ATP. J Immunol 187: 2365–2375.
132. Gu BJ, Sluyter R, Skarratt KK, Shemon AN, Dao-Ung L-P, Fuller SJ, Barden JA, Clarke AL, Petrou S, and Wiley JS (2004) An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem 279:31287–31295.
133. Gu BJ and Wiley JS (2006) Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 107:4946–4953.
134. Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-Ung P, Petrou S, Barden JA, and Wiley JS (2001) A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 276:11135–11142.
135. 7) receptors. Am J Physiol Cell Physiol 279:C1189–C1197.
136. Gunosewoyo H and Kassiou M (2010) P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat 20:625–646.
137. Haag F, Koch-Nolte F, Kühl M, Lorenzen S, and Thiele HG (1994) Premature stop codons inactivate the RT6 genes of the human and chimpanzee species. J Mol Biol 243:537–546.
138. Hansen RR, Nielsen CK, Nasser A, Thomsen SIM, Eghorn LF, Pham Y, Schulenburg C, Syberg S, Ding M, and Stojilkovic SS, et al. (2011) P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain 152:1766–1776.
139. Hassler M and Ladurner AG (2012) Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases. Curr Opin Struct Biol 22:721–729.
140. Hatcher JP, Chessell IP, and Hughes JP (2011) Biologics: the next-generation therapeutics for analgesia? Expert Rev Neurother 11:1653–1658.
141. Hattori F, Ohshima Y, Seki S, Tsukimoto M, Sato M, Takenouchi T, Suzuki A, Takai E, Kitani H, and Harada H, et al. (2012) Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7. Eur J Pharmacol 695:20–26.
142. Hattori M and Gouaux E (2012) Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485:207–212.
143. He WJ, Cui J, Du L, Zhao YD, Burnstock G, Zhou HD, and Ruan HZ (2012) Spinal P2X(7) receptor mediates microglia activation-induced neuropathic pain in the sciatic nerve injury rat model. Behav Brain Res 226:163–170.
144. He Y, Franchi L, and Núñez G (2013) TLR agonists stimulate Nlrp3-dependent IL-1b production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol 190:334–339.
145. Hempel C, Nörenberg W, Sobottka H, Urban N, Nicke A, Fischer W, and Schaefer M (2013) The phenothiazine-class antipsychotic drugs prochlorperazine and tri-fluoperazine are potent allosteric modulators of the human P2X7 receptor. Neu-ropharmacology 75:365–379.
146. 7) receptor-mediated reactive oxygen and nitrogen species formation: from receptor to generators. Biochem Soc Trans 35: 1168–1170.
147. Hibell AD, Thompson KM, Xing M, Humphrey PPA, and Michel AD (2001) Complexities of measuring antagonist potency at P2X(7) receptor orthologs. J Pharmacol Exp Ther 296:947–957.
148. Hong S, Brass A, Seman M, Haag F, Koch-Nolte F, and Dubyak GR (2007) Lipo-polysaccharide, IFN-g, and IFN-b induce expression of the thiol-sensitive ART2.1 Ecto-ADP-ribosyltransferase in murine macrophages. J Immunol 179:6215–6227.
149. Hong S, Schwarz N, Brass A, Seman M, Haag F, Koch-Nolte F, Schilling WP, and Dubyak GR (2009) Differential regulation of P2X7 receptor activation by extracellular nicotinamide adenine dinucleotide and ecto-ADP-ribosyltransferases in murine macrophages and T cells. J Immunol 183:578–592.
150. Honore P, Donnelly-Roberts D, Namovic M, Zhong C, Wade C, Chandran P, Zhu C, Carroll W, Perez-Medrano A, and Iwakura Y, et al. (2009) The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res 204:77–81.
151. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, and Chandran P, et al. (2006) A-740003 [N-(1-[(cyanoimino) (5-quinolinylamino) methyl]amino-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 319:1376–1385.
152. Hoque R, Sohail M, Malik A, Sarwar S, Luo Y, Shah A, Barrat F, Flavell R, Gorelick F, and Husain S, et al. (2011) TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Gastroenterology 141:358–369.
153. Hoque R, Sohail MA, Salhanick S, Malik AF, Ghani A, Robson SC, and Mehal WZ (2012) P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am J Physiol Gastrointest Liver Physiol 302:G1171–G1179.
154. Hu H, Lu W, Zhang M, Zhang X, Argall AJ, Patel S, Lee GE, Kim YC, Jacobson KA, and Laties AM, et al. (2010) Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res 91:425–432.
155. Humphreys BD and Dubyak GR (1998) Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 64:265–273.
156. Ichinari K, Kakei M, Matsuoka T, Nakashima H, and Tanaka H (1996) Direct activation of the ATP-sensitive potassium channel by oxygen free radicals in guinea-pig ventricular cells: its potentiation by MgADP. J Mol Cell Cardiol 28:1867–1877.
157. Ishii K, Kaneda M, Li H, Rockland KS, and Hashikawa T (2003) Neuron-specific distribution of P2X7 purinergic receptors in the monkey retina. J Comp Neurol 459:267–277.
158. Ito G, Suekawa Y, Watanabe M, Takahashi K, Inubushi T, Murasaki K, Hirose N, Hiyama S, Uchida T, and Tanne K (2013) P2X7 receptor in the trigeminal sensory nuclear complex contributes to tactile allodynia/hyperalgesia following trigeminal nerve injury. Eur J Pain 17:185–199.
159. Itoh K, Chiang CY, Li Z, Lee JC, Dostrovsky JO, and Sessle BJ (2011) Central sensitization of nociceptive neurons in rat medullary dorsal horn involves puri-nergic P2X7 receptors. Neuroscience 192:721–731.
160. Iwamaru Y, Takenouchi T, Murayama Y, Okada H, Imamura M, Shimizu Y, Hashimoto M, Mohri S, Yokoyama T, and Kitani H (2012) Anti-prion activity of brilliant blue G. PLoS ONE 7:e37896.
161. Jalilian I, Peranec M, Curtis BL, Seavers A, Spildrejorde M, Sluyter V, and Sluyter R (2012a) Activation of the damage-associated molecular pattern receptor P2X7 induces interleukin-1b release from canine monocytes. Vet Immunol Immunopa-thol 149:86–91.
162. Jalilian I, Spildrejorde M, Seavers A, Curtis BL, McArthur JD, and Sluyter R (2012b) Functional expression of the damage-associated molecular pattern receptor P2X7 on canine kidney epithelial cells. Vet Immunol Immunopathol 150:228-233.
163. Jamieson SE, Peixoto-Rangel AL, Hargrave AC, Roubaix LAD, Mui EJ, Boulter NR, Miller EN, Fuller SJ, Wiley JS, and Castellucci L, et al. (2010) Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes Immun 11:374-383.
164. Jelassi B, Anchelin M, Chamouton J, Cayuela ML, Clarysse L, Li J, Goré J, Jiang LH, and Roger S (2013) Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis 34:1487-1496.
165. Ji X, Naito Y, Hirokawa G, Weng H, Hiura Y, Takahashi R, and Iwai N (2012) P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res 35:173-179.
166. Jiang LH (2012) P2X receptor-mediated ATP purinergic signaling in health and disease. Cell Health Cytoskelet 4:83-101.
167. Jiang LH (2009) Inhibition of P2X(7) receptors by divalent cations: old action and new insight. Eur Biophys J 38:339-346.
168. Jiang LH, Baldwin JM, Roger S, and Baldwin SA (2013) Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol 4:55.
169. Jiang LH, Mackenzie AB, North RA, and Surprenant A (2000) Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 58:82-88.
170. Jimenez-Pacheco A, Mesuret G, Sanz-Rodriguez A, Tanaka K, Mooney C, Conroy R, Miras-Portugal MT, Diaz-Hernandez M, Henshall DC, and Engel T (2013) Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia 54:1551-1561.
171. Jørgensen NR, Husted LB, Skarratt KK, Stokes L, Tofteng CL, Kvist T, Jensen J-EB, Eiken P, Brixen K, and Fuller S, et al. (2012) Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur J Hum Genet 20:675-681.
172. Kakurai K, Sugiyama T, Kurimoto T, Oku H, and Ikeda T (2013) Involvement of P2X (7) receptors in retinal ganglion cell death after optic nerve crush injury in rats. Neurosci Lett 534:237-241.
173. Kamei J, Takahashi Y, Yoshikawa Y, and Saitoh A (2005) Involvement of P2X receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity. Eur J Pharmacol 528:158-161.
174. Kanaitsuka T, Bortell R, Stevens LA, Moss J, Sardinha D, Rajan TV, Zipris D, Mordes JP, Greiner DL, and Rossini AA (1997) Expression in BALB/c and C57BL/6 mice of Rt6-1 and Rt6-2 ADP-ribosyltransferases that differ in enzymatic activity: C57BL/6 Rt6-1 is a natural transferase knockout. J Immunol 159:2741-2749.
175. Kang SS, Keasey MP, and Hagg T (2013) P2X7 receptor inhibition increases CNTF in the subventricular zone, but not neurogenesis or neuroprotection after stroke in adult mice. Transl Stroke Res 4:533-545.
176. Kawate T, Michel JC, Birdsong WT, and Gouaux E (2009) Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 460:592-598.
177. Ke HZ, Qi H, Weidema AF, Zhang Q, Panupinthu N, Crawford DT, Grasser WA, Paralkar VM, Li M, and Audoly LP, et al. (2003) Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol 17:1356-1367.
178. Kerr D and Krantis A (1979) A new class of ATP antagonist. Proc Aust Physiol Pharmacol Soc 10:156P.
179. Kerur N, Hirano Y, Tarallo V, Fowler BJ, Bastos-Carvalho A, Yasuma T, Yasuma R, Kim Y, Hinton DR, and Kirschning CJ, et al. (2013) TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy. Invest Ophthalmol Vis Sci 54:7395-7401.
180. Keystone EC, Wang MM, Layton M, Hollis S, and McInnes IB; D1520C00001 Study Team (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 71:1630-1635.
181. Khadra A, Tomic M, Yan Z, Zemkova H, Sherman A, and Stojilkovic SS (2013) Dual gating mechanism and function of P2X7 receptor channels. Biophys J 104:2612-2621.
182. Kim JE and Kang TC (2011) The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. J Clin Invest 121:2037-2047.
183. Kim JE, Ryu HJ, and Kang TC (2011) P2X7 receptor activation ameliorates CA3 neuronal damage via a tumor necrosis factor-a-mediated pathway in the rat hippocampus following status epilepticus. J Neuroinflammation 8:62.
184. Kim WI, Ryu HJ, Kim JE, Seo CH, Lee BC, Choi IG, and Kang TC (2013) Differential nuclear factor-kappa B phosphorylation induced by lipopolysaccharide in the hippocampus of P2X7 receptor knockout mouse. Neurol Res 35:369-381.
185. Kim JE, Ryu HJ, Yeo SI, and Kang TC (2010) P2X7 receptor regulates leukocyte infiltrations in rat frontoparietal cortex following status epilepticus. J Neuroinflammation 7:65.
186. Koch-Nolte F, Duffy T, Nissen M, Kahl S, Killeen N, Ablamunits V, Haag F, and Leiter EH (1999) A new monoclonal antibody detects a developmentally regulated mouse ecto-ADP-ribosyltransferase on T cells: subset distribution, inbred strain variation, and modulation upon T cell activation. J Immunol 163: 6014-6022.
187. Koch-Nolte F, Reyelt J, Schössow B, Schwarz N, Scheuplein F, Rothenburg S, Haag F, Alzogaray V, Cauerhff A, and Goldbaum FA (2007) Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB J 21:3490-3498.
188. Kong F, Liu S, Xu C, Liu J, Li G, Li G, Gao Y, Lin H, Tu G, and Peng H, et al. (2013) Electrophysiological studies of upregulated P2X7 receptors in rat superior cervical ganglia after myocardial ischemic injury. Neurochem Int 63:230-237.
189. Korcok J, Raimundo LN, Ke HZ, Sims SM, and Dixon SJ (2004) Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. J Bone Miner Res 19:642-651.
190. Kurashima Y, Amiya T, Nochi T, Fujisawa K, Haraguchi T, Iba H, Tsutsui H, Sato S, Nakajima S, and Iijima H, et al. (2012) Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun 3: 1034.
191. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, and Gabel CA (2002) Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 168: 6436–6445.
192. Laeremans T, Stortelers C, Nolte F, Gonzalez M, Assuncao J, and Van Rompaey P (2010) Inventors, Ablynx, assignee. Genetic immunization for producing immuno-globulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4, Ablynx N.V. Patent WO2010070145. 2010 Dec 2.
193. Lambrecht G, Friebe T, Grimm U, Windscheif U, Bungardt E, Hildebrandt C, Bäumert HG, Spatz-Kümbel G, and Mutschler E (1992) PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol 217:217–219.
194. Lang PA, Merkler D, Funkner P, Shaabani N, Meryk A, Krings C, Barthuber C, Recher M, Brück W, and Häussinger D, et al. (2010) Oxidized ATP inhibits T-cell-mediated autoimmunity. Eur J Immunol 40:2401–2408.
195. Le Feuvre RA, Brough D, Touzani O, and Rothwell NJ (2003) Role of P2X7 receptors in ischemic and excitotoxic brain injury in vivo. J Cereb Blood Flow Metab 23: 381–384.
196. Le Stunff H, Auger R, Kanellopoulos J, and Raymond MN (2004) The Pro-451 to Leu polymorphism within the C-terminal tail of P2X7 receptor impairs cell death but not phospholipase D activation in murine thymocytes. J Biol Chem 279: 16918–16926.
197. Lee GE, Joshi BV, Chen W, Jeong LS, Moon HR, Jacobson KA, and Kim YC (2008a) Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. Bioorg Med Chem Lett 18:571–575.
198. Lee M, Lee SJ, Choi HJ, Jung YW, Frøkiaer J, Nielsen S, and Kwon TH (2008b) Regulation of AQP4 protein expression in rat brain astrocytes: role of P2X7 receptor activation. Brain Res 1195:1–11.
199. Lemaire I and Leduc N (2003) Purinergic P2X7 receptor function in lung alveolar macrophages: Pharmacologic characterization and bidirectional regulation by Th1 and Th2 cytokines. Drug Dev Res 59:118–127.
200. Lenertz LY, Gavala ML, Hill LM, and Bertics PJ (2009) Cell signaling via the P2X(7) nucleotide receptor: linkage to ROS production, gene transcription, and receptor trafficking. Purinergic Signal 5:175–187.
201. Lenertz LY, Gavala ML, Zhu Y, and Bertics PJ (2011) Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol Res 50:22–38.
202. Lester S, Stokes L, Skarratt KK, Gu BJ, Sivils KL, Lessard CJ, Wiley JS, and Rischmueller M (2013) Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren’s syndrome. Arthritis Res Ther 15:R71.
203. Letavic MA, Lord B, Bischoff F, Hawryluk NA, Pieters S, Rech JC, Sales Z, Velter AI, Ao H, and Bonaventure P, et al. (2013) Synthesis and pharmacological characterization of two novel, brain penetrating P2X7 antagonists. ACS Med Chem Lett 4: 419–422.
204. Li CM, Campbell SJ, Kumararatne DS, Hill AV, and Lammas DA (2002) Response heterogeneity of human macrophages to ATP is associated with P2X7 receptor expression but not to polymorphisms in the P2RX7 promoter. FEBS Lett 531: 127–131.
205. Li M, Chang TH, Silberberg SD, and Swartz KJ (2008) Gating the pore of P2X receptor channels. Nat Neurosci 11:883–887.
206. 2+. Proc Natl Acad Sci USA 110:E3455–E3463.
207. +-induced vasotoxicity in the pericyte-containing microvasculature of the rat retina: effect of diabetes. Invest Ophthalmol Vis Sci 47: 5032–5038.
208. Lin C, Ren S, Zhang L, Jin H, Sun J, and Zuo Y (2012) Extracellular ATP induces CD44 shedding from macrophage-like P388D1 cells via the P2X7 receptor. Hematol Oncol 30:70–75.
209. Liu J, Li G, Peng H, Tu G, Kong F, Liu S, Gao Y, Xu H, Qiu S, and Fan B, et al. (2013) Sensory-sympathetic coupling in superior cervical ganglia after myocardial ische-mic injury facilitates sympathoexcitatory action via P2X7 receptor. Purinergic Signal 9:463–479.
210. Liu L, Zou J, Liu X, Jiang LH, and Li J (2010) Inhibition of ATP-induced macrophage death by emodin via antagonizing P2X7 receptor. Eur J Pharmacol 640:15–19.
211. Liu X, Surprenant A, Mao HJ, Roger S, Xia R, Bradley H, and Jiang LH (2008) Identification of key residues coordinating functional inhibition of P2X7 receptors by zinc and copper. Mol Pharmacol 73:252–259.
212. Lopez-Castejon G, Theaker J, Pelegrin P, Clifton AD, Braddock M, and Surprenant A (2010) P2X(7) receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J Immunol 185:2611–2619.
213. Lu YM, Tao RR, Huang JY, Li LT, Liao MH, Li XM, Fukunaga K, Hong ZH, and Han F (2012) P2X7 signaling promotes microsphere embolism-triggered microglia activation by maintaining elevation of Fas ligand. J Neuroinflammation 9:172.
214. Lucae S, Salyakina D, Barden N, Harvey M, Gagné B, Labbé M, Binder EB, Uhr M, Paez-Pereda M, and Sillaber I, et al. (2006) P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 15:2438–2445.
215. Lucattelli M, Cicko S, Müller T, Lommatzsch M, De Cunto G, Cardini S, Sundas W, Grimm M, Zeiser R, and Dürk T, et al. (2011) P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol 44:423–429.
216. Ludden PW (1994) Reversible ADP-ribosylation as a mechanism of enzyme regulation in procaryotes. Mol Cell Biochem 138:123–129.
217. Marcellino D, Suárez-Boomgaard D, Sánchez-Reina MD, Aguirre JA, Yoshitake T, Yoshitake S, Hagman B, Kehr J, Agnati LF, and Fuxe K, et al. (2010) On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: studies with the P2X(7) receptor antagonist A-438079. J Neural Transm 117:681–687.
218. Marcillo A, Frydel B, Bramlett HM, and Dietrich WD (2012) A reassessment of P2X7 receptor inhibition as a neuroprotective strategy in rat models of contusion injury. Exp Neurol 233:687–692.
219. Marcoli M, Cervetto C, Paluzzi P, Guarnieri S, Alloisio S, Thellung S, Nobile M, and Maura G (2008) P2X7 pre-synaptic receptors in adult rat cerebrocortical nerve terminals: a role in ATP-induced glutamate release. J Neurochem 105:2330–2342.
220. Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, and Guimaraes MZ (2011) Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol 163:912–926.
221. Martin U, Scholler J, Gurgel J, Renshaw B, Sims JE, and Gabel CA (2009) External-ization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages. J Immunol 183:4021–4030.
222. Martins JP, Silva RBM, Coutinho-Silva R, Takiya CM, Battastini AMO, Morrone FB, and Campos MM (2012) The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice. Br J Pharmacol 165:183–196.
223. Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC, and Murrell-Lagnado R (2012) Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. Br J Pharmacol 165:978–993.
224. Matute C, Torre I, Pérez-Cerdá F, Pérez-Samartín A, Alberdi E, Etxebarria E, Arranz AM, Ravid R, Rodríguez-Antigüedad A, and Sánchez-Gómez M, et al. (2007) P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 27:9525–9533.
225. McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang XF, Shieh CC, Wismer CT, Zhu CZ, and Gauvin DM, et al. (2007) P2X7-related modulation of pathological nociception in rats. Neuroscience 146:1817–1828.
226. McHugh SM, Roman S, Davis B, Koch A, Pickett AM, Richardson JC, Miller SR, Wetten S, Cox CJ, and Karpe F, et al. (2012) Effects of genetic variation in the P2RX7 gene on pharmacodynamics of a P2X(7) receptor antagonist: a prospective genotyping approach. Br J Clin Pharmacol 74:376–380.
227. Melani A, Amadio S, Gianfriddo M, Vannucchi MG, Volontè C, Bernardi G, Pedata F, and Sancesario G (2006) P2X7 receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. J Cereb Blood Flow Metab 26:974–982.
228. Menzies RI, Unwin RJ, Dash RK, Beard DA, Cowley AW Jr, Carlson BE, Mullins JJ, and Bailey MA (2013) Effect of P2X4 and P2X7 receptor antagonism on the pressure diuresis relationship in rats. Front Physiol 4:305.
229. Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, and Chessell IP (2007) Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol 151:103–114.
230. Michel AD, Clay WC, Ng SW, Roman S, Thompson K, Condreay JP, Hall M, Holbrook J, Livermore D, and Senger S (2008) Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects. Br J Pharmacol 155:738–751.
231. Michel AD and Fonfria E (2007) Agonist potency at P2X7 receptors is modulated by structurally diverse lipids. Br J Pharmacol 152:523–537.
232. Michel AD, Ng SW, Roman S, Clay WC, Dean DK, and Walter DS (2009) Mechanism of action of species-selective P2X(7) receptor antagonists. Br J Pharmacol 156: 1312–1325.
233. Michel AD, Thompson KM, Simon J, Boyfield I, Fonfria E, and Humphrey PP (2006) Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function. Br J Pharmacol 149:948–957.
234. Miller CM, Boulter NR, Fuller SJ, Zakrzewski AM, Lees MP, Saunders BM, Wiley JS, and Smith NC (2011) The role of the P2X₇ receptor in infectious diseases. PLoS Pathog 7:e1002212.
235. Mingam R, De Smedt V, Amédée T, Bluthé RM, Kelley KW, Dantzer R, and Layé S (2008) In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1 b in the murine brain. Brain Behav Immun 22:234–244.
236. Monif M, Reid CA, Powell KL, Smart ML, and Williams DA (2009) The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neu-rosci 29:3781–3791.
237. Moon H, Na H-Y, Chong KH, and Kim TJ (2006) P2X7 receptor-dependent ATP-induced shedding of CD27 in mouse lymphocytes. Immunol Lett 102:98–105.
238. Moore SF and Mackenzie AB (2008) Species and agonist dependent zinc modulation of endogenous and recombinant ATP-gated P2X7 receptors. Biochem Pharmacol 76:1740–1747.
239. Moore SF and MacKenzie AB (2009) NADPH oxidase NOX2 mediates rapid cellular oxidation following ATP stimulation of endotoxin-primed macrophages. J Immunol 183:3302–3308.
240. Mueller-Dieckmann C, Scheuermann T, Wursthorn K, Schröder J, Haag F, Schulz GE, and Koch-Nolte F (2002) Expression, purification, crystallization and preliminary X-ray analysis of rat ecto-ADP-ribosyltransferase 2 (ART2.2). Acta Crys-tallogr D Biol Crystallogr 58:1211–1213.
241. Müller T, Vieira RP, Grimm M, Dürk T, Cicko S, Zeiser R, Jakob T, Martin SF, Blumenthal B, and Sorichter S, et al. (2011) A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol 44: 456–464.
242. + efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38:1142–1153.
243. Murgia M, Hanau S, Pizzo P, Rippa M, and Di Virgilio F (1993) Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem 268: 8199–8203.
244. Muzzachi S, Blasi A, Ciani E, Favia M, Cardone RA, Marzulli D, Reshkin SJ, Merizzi G, Casavola V, and Soleti A, et al. (2013) MED1101: a new dialdehydic compound regulating P2x7 receptor cell surface expression in U937 cells. Biol Cell 105: 399-413.
245. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, and Kim HP, et al. (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12:222-230.
246. Nakanishi M, Mori T, Nishikawa K, Sawada M, Kuno M, and Asada A (2007) The effects of general anesthetics on P2X7 and P2Y receptors in a rat microglial cell line. Anesth Analg 104:1136-1144.
247. Naviaux RK, Zolkipli Z, Wang L, Nakayama T, Naviaux JC, Le TP, Schuchbauer MA, Rogac M, Tang Q, and Dugan LL, et al. (2013) Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. PLoS ONE 8:e57380.
248. Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, and Niforatos W, et al. (2006) Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem 49:3659-3666.
249. Nicke A (2008) Homotrimeric complexes are the dominant assembly state of native P2X7 subunits. Biochem Biophys Res Commun 377:803-808.
250. Nicke A, Bäumert HG, Rettinger J, Eichele A, Lambrecht G, Mutschler E, and Schmalzing G (1998) P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J 17:3016-3028.
251. Nicke A, Kuan YH, Masin M, Rettinger J, Marquez-Klaka B, Bender O, Górecki DC, Murrell-Lagnado RD, and Soto F (2009) A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem 284:25813-25822.
252. Nörenberg W, Hempel C, Urban N, Sobottka H, Illes P, and Schaefer M (2011) Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations. J Biol Chem 286:11067-11081.
253. Nörenberg W, Sobottka H, Hempel C, Plötz T, Fischer W, Schmalzing G, and Schaefer M (2012) Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors. Br J Pharmacol 167:48-66.
254. Notomi S, Hisatomi T, Murakami Y, Terasaki H, Sonoda S, Asato R, Takeda A, Ikeda Y, Enaida H, and Sakamoto T, et al. (2013) Dynamic increase in extracellular ATP accelerates photoreceptor cell apoptosis via ligation of P2RX7 in subretinal hemorrhage. PLoS ONE 8:e53338.
255. Ohshima Y, Tsukimoto M, Takenouchi T, Harada H, Suzuki A, Sato M, Kitani H, and Kojima S (2010) 7-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta 1800:40-46.
256. Okamoto S, Azhipa O, Yu Y, Russo E, and Dennert G (1998) Expression of ADP-ribosyltransferase on normal T lymphocytes and effects of nicotinamide adenine dinucleotide on their function. J Immunol 160:4190-4198.
257. Panenka W, Jijon H, Herx LM, Armstrong JN, Feighan D, Wei T, Yong VW, Ransohoff RM, and MacVicar BA (2001) P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. JNeurosci 21:7135-7142.
258. Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, Muyldermans S, Hol WG, Kobilka BK, and Steyaert J (2014) A general protocol for the generation of Nanobodies for structural biology. Nat Protoc 9:674-693.
259. Pelegrin P, Barroso-Gutierrez C, and Surprenant A (2008) P2X7 receptor differentially couples to distinct release pathways for IL-1p in mouse macrophage. J Immunol 180: 7147-7157.
260. Pelegrin P and Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1p release by the ATP-gated P2X7 receptor. EMBO J 25: 5071-5082.
261. Pellegatti P, Falzoni S, Donvito G, Lemaire I, and Di Virgilio F (2011) P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB J 25:1264-1274.
262. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, and Di Virgilio F (2005) A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell 16:3659-3665.
263. Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L, Takano T, Tian GF, Goldman SA, and Nedergaard M (2009) Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 106:12489-12493.
264. Perez-Medrano A, Donnelly-Roberts DL, Honore P, Hsieh GC, Namovic MT, Peddi S, Shuai Q, Wang Y, Faltynek CR, and Jarvis MF, et al. (2009) Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain. J Med Chem 52:3366-3376.
265. Portales-Cervantes L, Niño-Moreno P, Doníz-Padilla L, Baranda-Candido L, García-Hernández M, Salgado-Bustamante M, González-Amaro R, and Portales-Pérez D (2010) Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum Immunol 71: 818-825.
266. Pupovac A, Foster CM, and Sluyter R (2013a) Human P2X7 receptor activation induces the rapid shedding of CXCL16. Biochem Biophys Res Commun 432: 626-631.
267. Pupovac A, Stokes L, and Sluyter R (2013b) CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation. Purinergic Signal 9: 609-619.
268. Puthussery T and Fletcher E (2009) Extracellular ATP induces retinal photoreceptor apoptosis through activation of purinoceptors in rodents. J Comp Neurol 513: 430-440.
269. Qiu F and Dahl G (2009) A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP. Am J Physiol Cell Physiol 296:C250-C255.
270. Qu Y and Dubyak GR (2009) P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways. Purinergic Signal 5: 163-173.
271. Qu Y, Misaghi S, Newton K, Gilmour LL, Louie S, Cupp JE, Dubyak GR, Hackos D, and Dixit VM (2011) Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol 186:6553-6561.
272. Rahman OA, Sasvari-Szekely M, Szekely A, Faludi G, Guttman A, and Nemoda Z (2010) Analysis of a polymorphic microRNA target site in the purinergic receptor P2RX7 gene. Electrophoresis 31:1790-1795.
273. Rassendren F, Buell GN, Virginio C, Collo G, North RA, and Surprenant A (1997) The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 272:5482-5486.
274. Riedel T, Lozinsky I, Schmalzing G, and Markwardt F (2007a) Kinetics of P2X7 receptor-operated single channels currents. Biophys J 92:2377-2391.
275. Riedel T, Schmalzing G, and Markwardt F (2007b) Influence of extracellular monovalent cations on pore and gating properties of P2X7 receptor-operated single-channel currents. Biophys J 93:846-858.
276. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, Kanellopoulos J, Quesniaux VFJ, Marchand-Adam S, and Crestani B, et al. (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 182:774-783.
277. Rodriguez-Feo CL, Sexton KW, Boyer RB, Pollins AC, Cardwell NL, Nanney LB, Shack RB, Mikesh MA, McGill CH, and Driscoll CW, et al. (2013) Blocking the P2X7 receptor improves outcomes after axonal fusion. J Surg Res 184:705-713.
278. Roger S, Gillet L, Baroja-Mazo A, Surprenant A, and Pelegrin P (2010a) C-terminal calmodulin-binding motif differentially controls human and rat P2X7 receptor current facilitation. J Biol Chem 285:17514-17524.
279. Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA, Surprenant A, and Jiang LH (2010b) Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. JPsychiatr Res 44:347-355.
280. Roger S, Pelegrin P, and Surprenant A (2008) Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding. J Neurosci 28:6393-6401.
281. Rokic MB and Stojilkovic SS (2013) Two open states of P2X receptor channels. Front Cell Neurosci 7:215.
282. Romagnoli R, Baraldi PG, Cruz-Lopez O, Lopez-Cara C, Preti D, Borea PA, and Gessi S (2008) The P2X7 receptor as a therapeutic target. Expert Opin Ther Targets 12: 647-661.
283. Roman S, Cusdin FS, Fonfria E, Goodwin JA, Reeves J, Lappin SC, Chambers L, Walter DS, Clay WC, and Michel AD (2009) Cloning and pharmacological characterization of the dog P2X7 receptor. Br J Pharmacol 158:1513-1526.
284. Ryu JK, Jantaratnotai N, Serrano-Perez MC, McGeer PL, and McLarnon JG (2011) Block of purinergic P2X7R inhibits tumor growth in a C6 glioma brain tumor animal model. J Neuropathol Exp Neurol 70:13-22.
285. Ryu JK and McLarnon JG (2008) Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer’s disease. Neuroreport 19: 1715-1719.
286. Sánchez-Nogueiro J, Marín-García P, and Miras-Portugal MT (2005) Characterization of a functional P2X(7)-like receptor in cerebellar granule neurons from P2X(7) knockout mice. FEBS Lett 579:3783-3788.
287. Sanz JM, Chiozzi P, Ferrari D, Colaianna M, Idzko M, Falzoni S, Fellin R, Trabace L, and Di Virgilio F (2009) Activation of microglia by amyloid /3 requires P2X7 receptor expression. J Immunol 182:4378-4385.
288. 2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma. Neuropharmacology 75: 380-390.
289. Sawynok J and Reid A (1997) Peripheral adenosine 5'-triphosphate enhances nociception in the formalin test via activation of a purinergic p2X receptor. Eur J Pharmacol 330:115-121.
290. + and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. J Immunol 182:2898-2908.
291. Schilling WP, Sinkins WG, and Estacion M (1999) Maitotoxin activates a nonselective cation channel and a P2Z/P2X(7)-like cytolytic pore in human skin fibroblasts. Am J Physiol 277:C755-C765.
292. Schwarz N, Drouot L, Nicke A, Fliegert R, Boyer O, Guse AH, Haag F, Adriouch S, and Koch-Nolte F (2012) Alternative splicing of the N-terminal cytosolic and transmembrane domains of P2X7 controls gating of the ion channel by ADP-ribosylation. PLoS ONE 7:e41269.
293. Seil M, Fontanils U, Etxebarria IG, Pochet S, Garcia-Marcos M, Marino A, and Dehaye J-P (2008) Pharmacological evidence for the stimulation of NADPH oxidase by P2X(7) receptors in mouse submandibular glands. Purinergic Signal 4: 347-355.
294. Seil M, Kabré E, Nagant C, Vandenbranden M, Fontanils U, Marino A, Pochet S, and Dehaye J-P (2010) Regulation by CRAMP of the responses of murine peritoneal macrophages to extracellular ATP. Biochim Biophys Acta 1798:569-578.
295. Seman M, Adriouch S, Scheuplein F, Krebs C, Freese D, Glowacki G, Deterre P, Haag F, and Koch-Nolte F (2003) NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19: 571-582.
296. Sesti F, Liu S, and Cai SQ (2010) Oxidation of potassium channels by ROS: a general mechanism of aging and neurodegeneration? Trends Cell Biol 20:45-51.
297. Sharp AJ, Polak PE, Simonini V, Lin SX, Richardson JC, Bongarzone ER, and Feinstein DL (2008) P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation 5:33.
298. Shemon AN, Sluyter R, Conigrave AD, and Wiley JS (2004) Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Br J Pharmacol 142:1015-1019.
299. Shemon AN, Sluyter R, Fernando SL, Clarke AL, Dao-Ung L-P, Skarratt KK, Saunders BM, Tan KS, Gu BJ, and Fuller SJ, et al. (2006) A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 281:2079-2086.
300. 7 receptor by a novel protein tyrosine kinase antagonist. Biochem Biophys Res Commun 365:515–520.
301. 7 receptor-stimulated phospholipase D activity in chronic lymphocytic leukaemia B-lymphocytes. Immunol Cell Biol 85:68–72.
302. Sim JA, Young MT, Sung HY, North RA, and Surprenant A (2004) Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci 24:6307–6314.
303. Skarratt KK, Fuller SJ, Sluyter R, Dao-Ung LP, Gu BJ, and Wiley JS (2005) A 59 intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1–2% of the Caucasian population. FEBS Lett 579:2675–2678.
304. Sluyter R, Shemon AN, Hughes WE, Stevenson RO, Georgiou JG, Eslick GD, Taylor RM, and Wiley JS (2007) Canine erythrocytes express the P2X7 receptor: greatly increased function compared with human erythrocytes. Am J Physiol Regul Integr Comp Physiol 293:R2090–R2098.
305. Sluyter R and Stokes L (2011) Significance of P2X7 receptor variants to human health and disease. Recent Pat DNA Gene Seq 5:41–54.
306. Smart ML, Gu B, Panchal RG, Wiley J, Cromer B, Williams DA, and Petrou S (2003) P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem 278:8853–8860.
307. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, and Gabel CA (2001) Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276:125–132.
308. Soltoff SP, McMillian MK, and Talamo BR (1989) Coomassie Brilliant Blue G is a more potent antagonist of P2 purinergic responses than Reactive Blue 2 (Ciba-cron Blue 3GA) in rat parotid acinar cells. Biochem Biophys Res Commun 165: 1279–1285.
309. Sorge RE, Trang T, Dorfman R, Smith SB, Beggs S, Ritchie J, Austin JS, Zaykin DV, Vander Meulen H, and Costigan M, et al. (2012) Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 18:595–599.
310. Sperlágh B, Vizi ES, Wirkner K, and Illes P (2006) P2X7 receptors in the nervous system. Prog Neurobiol 78:327–346.
311. Spildrejorde M, Curtis SJ, Curtis BL, and Sluyter R (2014) Extracellular adenosine 59-triphosphate and lipopolysaccharide induce interleukin-1b release in canine blood. Vet Immunol Immunopathol 157:105–110.
312. Steinberg TH and Silverstein SC (1987) Extracellular ATP42 promotes cation fluxes in the J774 mouse macrophage cell line. J Biol Chem 262:3118–3122.
313. 7 receptor mediates the uptake of organic cations in canine erythrocytes and mononuclear leukocytes: comparison to equivalent human cell types. Purinergic Signal 5: 385–394.
314. Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, and Mebus CA (2012) Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol 39:720–727.
315. Stokes L, Fuller SJ, Sluyter R, Skarratt KK, Gu BJ, and Wiley JS (2010) Two hap-lotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1b secretion. FASEB J 24: 2916–2927.
316. Stokes L, Jiang LH, Alcaraz L, Bent J, Bowers K, Fagura M, Furber M, Mortimore M, Lawson M, and Theaker J, et al. (2006) Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br J Pharmacol 149:880–887.
317. 2+ signaling. J Neurosci 26: 1378–1385.
318. Suadicani SO, Iglesias R, Spray DC, and Scemes E (2009) Point mutation in the mouse P2X7 receptor affects intercellular calcium waves in astrocytes. ASN Neuro 1:55–63.
319. 7 receptor activation may be involved in neuronal loss in the retinal ganglion cell layer after acute elevation of intraocular pressure in rats. Mol Vis 19:2080–2091.
320. 7). Science 272:735–738.
321. Syberg S, Schwarz P, Petersen S, Steinberg TH, Jensen J-EB, Teilmann J, and Jørgensen NR (2012) Association between P2X7 receptor polymorphisms and bone status in mice. J Osteoporos 2012:637986.
322. Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, Kitani H, and Hashimoto M (2010) P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 58: 91–96.
323. Taylor SRJ, Gonzalez-Begne M, Dewhurst S, Chimini G, Higgins CF, Melvin JE, and Elliott JI (2008) Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death. J Immunol 180:300–308.
324. Taylor SRJ, Gonzalez-Begne M, Sojka DK, Richardson JC, Sheardown SA, Harrison SM, Pusey CD, Tam FWK, and Elliott JI (2009a) Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7 responses. J Leukoc Biol 85:978–986.
325. Taylor SRJ, Turner CM, Elliott JI, McDaid J, Hewitt R, Smith J, Pickering MC, Whitehouse DL, Cook HT, and Burnstock G, et al. (2009b) P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol 20: 1275–1281.
326. Teixeira JM, Oliveira MCG, Nociti FH Jr, Clemente-Napimoga JT, Pelegrini-da-Silva A, Parada CA, and Tambeli CH (2010a) Involvement of temporomandibular joint P2X3 and P2X2/3 receptors in carrageenan-induced inflammatory hyperalgesia in rats. Eur J Pharmacol 645:79–85.
327. Teixeira JM, Oliveira MCG, Parada CA, and Tambeli CH (2010b) Peripheral mechanisms underlying the essential role of P2X7 receptors in the development of inflammatory hyperalgesia. Eur J Pharmacol 644:55–60.
328. Théâtre E, Frederix K, Guilmain W, Delierneux C, Lecut C, Bettendorff L, Bours V, and Oury C (2012) Overexpression of CD39 in mouse airways promotes bacteria-induced inflammation. J Immunol 189:1966-1974.
329. Thompson RJ, Jackson MF, Olah ME, Rungta RL, Hines DJ, Beazely MA, Mac-Donald JF, and MacVicar BA (2008) Activation of pannexin-1 hemichannels augments aberrant bursting in the hippocampus. Science 322:1555-1559.
330. Tschopp J (2011) Mitochondria: Sovereign of inflammation? Eur J Immunol 41: 1196-1202.
331. Tu G, Li G, Peng H, Hu J, Liu J, Kong F, Liu S, Gao Y, Xu C, and Xu X, et al. (2013) P2X(7) inhibition in stellate ganglia prevents the increased sympathoexcitatory reflex via sensory-sympathetic coupling induced by myocardial ischemic injury. Brain Res Bull 96:71-85.
332. Valdez-Morales E, Guerrero-Alba R, Liñán-Rico A, Espinosa-Luna R, Zarazua-Guzman S, Miranda-Morales M, Montaño LM, and Barajas-López C (2011) P2X7 receptors contribute to the currents induced by ATP in guinea pig intestinal myenteric neurons. Eur J Pharmacol 668:366-372.
333. Vergani A, Fotino C, D’Addio F, Tezza S, Podetta M, Gatti F, Chin M, Bassi R, Molano RD, and Corradi D, et al. (2013a) Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes 62:1665-1675.
334. Vergani A, Tezza S, D’Addio F, Fotino C, Liu K, Niewczas M, Bassi R, Molano RD, Kleffel S, and Petrelli A, et al. (2013b) Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation 127:463-475.
335. Verkhratsky A, Pankratov Y, Lalo U, and Nedergaard M (2012) P2X receptors in neuroglia. Wiley Interdiscip Rev Membr Transp Signal 1:151-161.
336. Virginio C, MacKenzie A, Rassendren FA, North RA, and Surprenant A (1999) Pore dilation of neuronal P2X receptor channels. Nat Neurosci 2:315-321.
337. Volonté C, Apolloni S, Skaper SD, and Burnstock G (2012) P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets 11:705-721.
338. Wang B and Sluyter R (2013) P2X7 receptor activation induces reactive oxygen species formation in erythroid cells. Purinergic Signal 9:101-112.
339. Wang J, Yang J, Liu P, Bi X, Li C, and Zhu K (2012) NAD induces astrocyte calcium flux and cell death by ART2 and P2X7 pathway. Am J Pathol 181:746-752.
340. Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P, Li P, Xu Q, Liu QS, and Goldman SA, et al. (2004) P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med 10:821-827.
341. Weber FC, Esser PR, Müller T, Ganesan J, Pellegatti P, Simon MM, Zeiser R, Idzko M, Jakob T, and Martin SF (2010) Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J Exp Med 207:2609-2619.
342. 7 function by the inflammatory cytokine IFNgamma in human epithelial cells. Biochim Biophys Acta 1788:1176-1187.
343. Westlund KN, Zhang L, Ma F, and Oz HS (2012) Chronic inflammation and pain in a tumor necrosis factor receptor (TNFR) (p55/p75—/—) dual deficient murine model. Transl Res 160:84-94.
344. Wiley JS, Dao-Ung L-P, Li C, Shemon AN, Gu BJ, Smart ML, Fuller SJ, Barden JA, Petrou S, and Sluyter R (2003) An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem 278: 17108-17113.
345. Wiley JS and Gu BJ (2012) A new role for the P2X7 receptor: a scavenger receptor for bacteria and apoptotic cells in the absence of serum and extracellular ATP. Purinergic Signal 8:579-586.
346. Wiley JS, Sluyter R, Gu BJ, Stokes L, and Fuller SJ (2011) The human P2X7 receptor and its role in innate immunity. Tissue Antigens 78:321-332.
347. Wilhelm K, Ganesan J, Müller T, Dürr C, Grimm M, Beilhack A, Krempl CD, Sorichter S, Gerlach UV, and Jüttner E, et al. (2010) Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 16:1434-1438.
348. Williams RO (2012) What have we learned about the pathogenesis of rheumatoid arthritis from TNF-targeted therapy? ISRN Immunol 2012:652739.
349. Wilson HL, Francis SE, Dower SK, and Crossman DC (2004) Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J Immunol 173:1202-1208.
350. Wilson HL, Varcoe RW, Stokes L, Holland KL, Francis SE, Dower SK, Surprenant A, and Crossman DC (2007) P2X receptor characterization and IL-1/IL-1Ra release from human endothelial cells. Br J Pharmacol 151:115-127.
351. Xie Y, Williams CD, McGill MR, Lebofsky M, Ramachandran A, and Jaeschke H (2013) Purinergic receptor antagonist A438079 protects against acetaminophen-induced liver injury by inhibiting p450 isoenzymes, not by inflammasome activation. Toxicol Sci 131:325-335.
352. Xu XJ, Boumechache M, Robinson LE, Marschall V, Gorecki DC, Masin M, and Murrell-Lagnado RD (2012) Splice variants of the P2X7 receptor reveal differential agonist dependence and functional coupling with pannexin-1. J Cell Sci 125:3776-3789.
353. Yan Z, Khadra A, Sherman A, and Stojilkovic SS (2011) Calcium-dependent block of P2X7 receptor channel function is allosteric. J Gen Physiol 138:437-452.
354. Yan Z, Li S, Liang Z, Tomic M, and Stojilkovic SS (2008) The P2X7 receptor channel pore dilates under physiological ion conditions. J Gen Physiol 132:563-573.
355. Yanagisawa D, Kitamura Y, Takata K, Hide I, Nakata Y, and Taniguchi T (2008) Possible involvement of P2X7 receptor activation in microglial neuroprotection against focal cerebral ischemia in rats. Biol Pharm Bull 31:1121-1130.
356. Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783: 673-694.
357. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, and Anand P (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6:12.
358. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA, and Junger WG (2009) Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J 23:1685-1693.
359. Young CNJ, Brutkowski W, Lien CF, Arkle S, Lochmüller H, Zabłocki K, and Górecki DC (2012) P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment. J Cell Mol Med 16:1026–1037.
360. Young MT, Pelegrin P, and Surprenant A (2006) Identification of Thr283 as a key determinant of P2X7 receptor function. Br J Pharmacol 149:261–268.
361. Young MT, Pelegrin P, and Surprenant A (2007) Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol 71:92–100.
362. Zanovello P, Bronte V, Rosato A, Pizzo P, and Di Virgilio F (1990) Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J Immunol 145:1545–1550.
363. Zhao J, Wang H, Dai C, Wang H, Zhang H, Huang Y, Wang S, Gaskin F, Yang N, and Fu SM (2013) P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway. Arthritis Rheum 65: 3176–3185.
364. Zhou ZH, Wang JX, Liu BJ, Li M, Lu Y, and Chen HS (2012) Contribution of the spinal P2X7 receptors to bee venom-induced nociception and inflammation in conscious rats. Neurosci Lett 531:145–148.
365. Zhu S, Wang Y, Wang X, Li J, and Hu F (2014) Emodin inhibits ATP-induced IL-1b secretion, ROS production and phagocytosis attenuation in rat peritoneal macro-phages via antagonizing P2X₇ receptor. Pharm Biol 52:51–57.